Search - tctmd.com

Displaying 101 - 120 of 238

Sort: Relevancy | Date

TCTMD’s Top 10 Most Popular Stories for November 2021

News Daily News

TCTMD’s Top 10 Most Popular Stories for November 2021

November 30, 2021

More Deaths With Bioprosthetic Than Mechanical AVR in Young AS Patients

News Conference News EACTS 2021

More Deaths With Bioprosthetic Than Mechanical AVR in Young AS Patients

Michael O'Riordan

October 18, 2021

Antithrombotic therapy does not provide a benefit for clinically stable but symptomatic outpatients with COVID-19, published results of the ACTIV-4b trial affirm. Neither aspirin nor apixaban (Eliquis; Bristol Myers Squibb) at prophylactic or therapeutic doses reduced what were already very low rates of major adverse cardiopulmonary outcomes versus placebo, and both modestly increased bleeding, researchers led by Jean Connors, MD (Brigham and Women’s Hospital, Boston, MA), report in a paper published online

News Daily News

ACTIV-4b: No Antithrombotic Therapy Needed for COVID-19 Outpatients

October 13, 2021

EMINENT: Better Patency With DES Over BMS for Fem-Pop Lesions

News Conference News VIVA 2021

EMINENT: Better Patency With DES Over BMS for Fem-Pop Lesions

October 12, 2021

Rivaroxaban Again Linked to More Bleeding vs Other DOACs

News Daily News

Rivaroxaban Again Linked to More Bleeding vs Other DOACs

October 11, 2021

Could an App Replace Statin Prescribing by Doctors?

News Daily News

Could an App Replace Statin Prescribing by Doctors?

Michael O'Riordan

September 08, 2021

Fixed-Dose Combo Therapy Slashes CVD Risk in Primary Prevention

News Conference News ESC 2021

Fixed-Dose Combo Therapy Slashes CVD Risk in Primary Prevention

Michael O'Riordan

August 31, 2021

Endpoint Reporting in Medical Journals Needs to Be Revamped: Review

News Daily News

Endpoint Reporting in Medical Journals Needs to Be Revamped: Review

Michael O'Riordan

August 17, 2021

Rivaroxaban Safe, Effective in Renal Disease: VOYAGER PAD

News Daily News

Rivaroxaban Safe, Effective in Renal Disease: VOYAGER PAD

August 10, 2021

Milrinone, Dobutamine Comparable for Cardiogenic Shock: DOREMI

News Daily News

Milrinone, Dobutamine Comparable for Cardiogenic Shock: DOREMI

August 10, 2021

COVID-19: TCTMD’s Daily Dispatch for August Week 2

News Daily News

COVID-19: TCTMD’s Daily Dispatch for August Week 2

August 08, 2021

STROKE-VT: DOACs Cut Cerebrovascular Events After LV Arrhythmia Ablation

News Conference News HRS 2021

STROKE-VT: DOACs Cut Cerebrovascular Events After LV Arrhythmia Ablation

July 29, 2021

J-Curve for Alcohol and AF Risk? UK Biobank Offers ‘Glimmer of Hope’

News Conference News HRS 2021

J-Curve for Alcohol and AF Risk? UK Biobank Offers ‘Glimmer of Hope’

July 28, 2021

COVID-19: TCTMD’s Daily Dispatch for July Week 4

News Daily News

COVID-19: TCTMD’s Daily Dispatch for July Week 4

July 26, 2021

Apixaban May Be Best DOAC for Frail, Older Patients With AF

News Daily News

Apixaban May Be Best DOAC for Frail, Older Patients With AF

July 19, 2021

Latest Statin Risk-Benefit Analysis: More Harm Than Good?

News Daily News

Latest Statin Risk-Benefit Analysis: More Harm Than Good?

Yael L. Maxwell

July 15, 2021

DOACs May Have Advantage Over VKAs After TAVI, Study Hints

News Daily News

DOACs May Have Advantage Over VKAs After TAVI, Study Hints

July 14, 2021

AHA Advice For Rare But Deadly Mechanical Complications of Acute MI

News Daily News

AHA Advice for Rare but Deadly Mechanical Complications of Acute MI

June 18, 2021

Closing the Gender Gap in Cardiology Clinical Trial Leadership: A Road Map

News Daily News

Closing the Gender Gap in Cardiology Clinical Trial Leadership: A Road Map

June 11, 2021

High Ischemic Risk and Bleeding Risk: A Delicate Balance Post-PCI

News Conference News EAS 2021

High Ischemic Risk and Bleeding Risk: A Delicate Balance Post-PCI

Michael O'Riordan

June 08, 2021

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.